ResearcherVeterans Health AdministrationNo recent work listed
David S. Yu
Matched on ORCID iD 0000-0002-2781-5379; OpenAlex author ID A5067547603. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 10
2013: 1 paper · 2014: 2 papers
Papers 3
- Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. Last author DOI 10.1038/onc.2013.488↗
- CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. Last author DOI 10.1158/0008-5472.can-13-1996↗
- Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. Last author DOI 10.1002/cncr.28144↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jerome Carl Landry · 3 shared papers, 2013–2014 · strength 0.09
- Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
- Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
- Paper Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage … DOI 10.1002/cncr.28144↗
- Lauren Elizabeth Colbert · 3 shared papers, 2013–2014 · strength 0.09
- Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
- Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
- Paper Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage … DOI 10.1002/cncr.28144↗
- William Adrian Hall · 3 shared papers, 2013–2014 · strength 0.09
- Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
- Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
- Paper Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage … DOI 10.1002/cncr.28144↗
- David A. Kooby · 3 shared papers, 2013–2014 · strength 0.09
- Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
- Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
- Paper Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage … DOI 10.1002/cncr.28144↗
- Volkan N. Adsay · 3 shared papers, 2013–2014 · strength 0.09
- Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
- Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
- Paper Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage … DOI 10.1002/cncr.28144↗
- Burcu Saka · 3 shared papers, 2013–2014 · strength 0.09
- Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
- Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
- Paper Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage … DOI 10.1002/cncr.28144↗
- Walter John Curran · 3 shared papers, 2013–2014 · strength 0.09
- Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
- Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
- Paper Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage … DOI 10.1002/cncr.28144↗
- Shishir Kumar Maithel · 3 shared papers, 2013–2014 · strength 0.09
- Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
- Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
- Paper Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage … DOI 10.1002/cncr.28144↗
- Bassel F. El‐Rayes · 3 shared papers, 2013–2014 · strength 0.09
- Paper Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy… DOI 10.1038/onc.2013.488↗
- Paper CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. DOI 10.1158/0008-5472.can-13-1996↗
- Paper Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage … DOI 10.1002/cncr.28144↗
- Ganji Purnachandra Nagaraju · 1 shared paper, 2014 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.